GENFIT

Capital/Financing Update • Jan 21, 2022

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille, France; Cambridge, MA; January 21, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a latestage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2021:

• 137,012 shares
• €512 873.86

During the second half of 2021, total trading was:

• On the buy side: 469,086 shares for a total amount of €1,824,630.43
• On the sell side: 437,124 shares for a total amount of €1,690,993.82

During this same period, the number of trades were:

• On the buy side: 1,402
• On the sell side: 1,389

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

• 27, 911 shares
• €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.

Its R&D is focused on three franchises: cholestatic diseases, Acute on Chronic Liver Failure (ACLF) and NASH diagnostics. In its cholestatic diseases franchise, ELATIVE™, a Phase 3 global trial evaluating elafibranor¹ in patients with Primary Biliary Cholangitis (PBC) is well underway following a successful Phase 2 clinical trial. Topline data is expected to be announced in early 2023. In 2021, GENFIT signed an exclusive licensing agreement with IPSEN ² to develop, manufacture and commercialize elafibranor in PBC and other indications. GENFIT is also developing GNS561¹ in cholangiocarcinoma following the acquisition of exclusive rights in this indication from Genoscience Pharma in 2021³ . In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated with data expected as early as the third quarter 2022. As part of its diagnostic solutions franchise, the Company entered into an agreement with Labcorp in 2021 to commercialize NASHnext®, powered by GENFIT's proprietary diagnostic technology NIS4® in identifying at-risk NASH.

GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext's regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT's largest shareholders and holds 8% of the company's share capital. www.genfit.com

GENFIT FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's research and development programs. The use of certain words, including "consider", "contemplate", "think", "aim", "expect", "understand", "should", "aspire", "estimate", "believe", "wish", "may", "could", "allow", "seek", "encourage" or "have confidence" or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and

¹ Elafibranor and GNS561 are investigational compounds that have not been reviewed nor been approved by a regulatory authority

² With the exception of China, Hong Kong, Taiwan, and Macau where Terns Pharmaceuticals holds the exclusive license to develop and commercialize elafibranor

³ Agreement includes commercialization and development in the United States, Canada and Europe, including the United Kingdom and Switzerland

uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, impact of the ongoing COVID-19 pandemic, exchange rate fluctuations and the Company's continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the French Autorité des Marchés Financiers ("AMF"), including those listed in Chapter 2 "Main Risks and Uncertainties" of the Company's 2020 Universal Registration Document filed with the AMF on 23 April 2021 under n° D.21-0350, which is available on the Company's website (www.genfit.com) and on the website of the AMF (www.amf-france.org), and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC") including the Company's 2020 Annual Report on Form 20-F filed with the SEC on April 23, 2021 and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

PRESS RELATIONS | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

APPENDIX H2 2021

	Buy side			Sell side
Date	Number of executions	Number of shares	Traded amounts in EUR	Number of executions	Number of shares	Traded amounts in EUR
TOTAL	1 402	469 086	1 824 630,43	1 389	437 124	1 690 993,82
01/07/	6	1838	5 927,40	2	996	3 231,01
2021 02/07/
2021	1	1	3,27	8	3006	9 867,79
05/07/	10	6251	21 381,61	35	19412	66 280,93
2021
06/07/ 2021	14	5903	20 275,97	11	1554	5 370,26
07/07/	18	7366	24 771,90	8	3386	11 647,61
2021
08/07/ 2021	5	1922	6 276,40	1	1	3,31
09/07/	2	101	331,46	7	1922	6 314,77
2021
12/07/ 2021	13	3209	10 423,77	1	1	3,29
13/07/	5	1547	4 940,57	9	1229	3 953,58
2021
14/07/ 2021	3	637	2 039,68	6	984	3 199,06
15/07/	7	2788	8 874,25	10	2024	6 455,01
2021
16/07/ 2021	9	2581	8 116,81	1	1	3,15
19/07/	12	2788	8 742,57	1	1	3,17
2021 20/07/
2021	4	1200	3 749,35	8	2113	6 625,59
21/07/	2	615	2 018,35	13	6462	20 919,52
2021 22/07/
2021	4	1294	4 205,50	4	671	2 203,53
23/07/	11	2888	9 620,97	15	3414	11 381,57
2021 26/07/
2021	10	2603	8 518,78	3	633	2 082,61
27/07/ 2021	4	730	2 333,11	1	1	3,23
28/07/ 2021	1	1	3,24	15	2709	8 881,56
29/07/ 2021	8	1452	4 816,39	3	775	2 597,77
30/07/	3	678	2 237,45	4	1355	4 517,58
2021

02/08/ 2021	9	3096	10 516,69	20	6727	22 839,93
03/08/ 2021	2	675	2 282,89	2	675	2 307,15
04/08/ 2021	1	1	3,36	1	1	3,36
05/08/ 2021	11	1759	5 879,14	1	1	3,36
06/08/ 2021	5	1045	3 460,29	1	1	3,35
09/08/ 2021	3	1310	4 304,05	7	1310	4 330,23
10/08/ 2021	4	1303	4 247,46	4	540	1 793,88
11/08/	1	1	3,25	3	1303	4 273,43
2021 12/08/	1	1	3,25	8	2264	7 602,81
2021 13/08/	1	1	3,31	1	1	3,31
2021 16/08/	1	1	3,28	1	1	3,28
2021 17/08/	1	1	3,26	1	1	3,26
2021 18/08/	2	1001	3 353,30	13	5675	19 190,25
2021 19/08/	3	2001	6 495,29	1	1	3,29
2021 20/08/	1	1	3,28	1	1	3,28
2021 23/08/	4	1001	3 291,30	1	1	3,30
2021 24/08/	5	2002	6 566,53	8	4001	13 227,28
2021 25/08/
2021 26/08/	12	1510	4 996,89	13	2035	6 748,11
2021 27/08/	6	863	2 823,78	5	596	1 963,66
2021 30/08/	5	1124	3 663,41	11	1391	4 556,31
2021 31/08/	4	287	941,92	3	327	1 079,72
2021 01/09/	25	5200	19 097,51	65	11300	40 558,11
2021 02/09/	28	4322	15 439,73	28	5752	21 071,16
2021 03/09/	10	1648	5 900,61	18	1751	6 310,35
2021	10	1466	5 230,00	9	1163	4 181,66
06/09/ 2021	7	935	3 359,48	6	1180	4 250,36
07/09/ 2021	10	1435	5 033,09	2	473	1 675,67
08/09/ 2021	9	1318	4 526,76	3	657	2 264,14

09/09/ 2021	3	522	1 762,27	10	1672	5 772,10
10/09/ 2021	15	1436	4 931,66	1	1	3,45
13/09/ 2021	7	1082	3 613,50	4	480	1 608,11
14/09/ 2021	6	782	2 598,61	3	246	826,56
15/09/ 2021	6	861	2 817,28	5	594	1 957,11
16/09/ 2021	1	1	3,27	8	856	2 831,12
17/09/ 2021	3	469	1 557,12	4	469	1 571,16
20/09/ 2021	9	1283	4 201,89	3	479	1 577,41
21/09/ 2021	9	920	2 970,21	1	1	3,25
22/09/ 2021	6	1177	3 814,10	7	2353	7 701,95
23/09/ 2021	12	1877	6 223,17	10	2183	7 279,89
24/09/ 2021	4	515	1 681,98	10	2103	7 025,63
27/09/ 2021	17	3045	10 187,52	14	3402	11 466,57
28/09/ 2021	4	969	3 242,23	2	21	70,52
29/09/ 2021	4	479	1 571,96	3	258	847,80
30/09/ 2021	4	772	2 521,39	4	524	1 722,00
01/10/ 2021	5	663	2 173,13	8	1325	4 374,97
04/10/ 2021	7	1976	6 429,90	1	1	3,25
05/10/ 2021	1	1	3,25	1	1	3,25
06/10/ 2021	7	1776	5 749,14	2	446	1 453,97
07/10/ 2021	1	1	3,24	2	50	162,00
08/10/ 2021	2	417	1 338,58	1	1	3,22
11/10/ 2021	3	948	3 014,64	2	425	1 361,68
12/10/ 2021	5	541	1 731,20	6	2003	6 453,80
13/10/ 2021	2	456	1 454,66	5	1737	5 635,67
14/10/ 2021	6	1282	4 149,56	5	493	1 601,10
15/10/ 2021	5	418	1 341,78	2	418	1 357,63
18/10/ 2021	1	1	3,24	1	1	3,24

19/10/ 2021	5	287	915,54	1	1	3,20
20/10/ 2021	1	1	3,22	1	1	3,22
21/10/ 2021	1	1	3,22	1	1	3,22
22/10/	4	662	2 132,33	1	1	3,25
2021 25/10/	4	692	2 207,66	1	1	3,25
2021 26/10/	3	500	1 589,50	1	250	797,50
2021 27/10/
2021 28/10/	10	1702	5 333,70	1	1	3,16
2021	13	2963	9 049,62	14	2076	6 311,24
29/10/ 2021	3	624	1 899,97	11	2574	7 929,44
01/11/ 2021	2	375	1 182,68	12	1588	4 991,89
02/11/ 2021	7	1457	4 557,43	12	831	2 614,68
03/11/ 2021	40	7282	23 463,05	52	9135	29 608,83
04/11/ 2021	14	2969	9 343,12	10	2123	6 722,38
05/11/ 2021	9	1655	5 151,86	11	1757	5 504,87
08/11/ 2021	6	1176	3 661,62	16	1520	4 788,58
09/11/	12	1899	6 008,83	10	2805	8 956,42
2021 10/11/	10	1472	4 672,94	7	976	3 120,04
2021 11/11/	5	288	914,69	1	1	3,18
2021 12/11/	4	468	1 468,92	3	257	821,33
2021 15/11/	2	312	978,44	2	312	984,66
2021 16/11/	6	671	2 092,38	1	1	3,13
2021 17/11/	4	288	889,92	6	611	1 910,67
2021 18/11/	5	1468	4 529,18	1	1	3,14
2021 19/11/	21	4493	14 438,30	29	6362	20 445,06
2021 22/11/20	13	2504	7 835,33	4	769	2 428,38
21 23/11/	3	1172	3 614,21
2021 24/11/
2021 25/11/	3	878	2 673,75	3	418	1 279,09
2021	5	1209	3 689,89	6	842	2 592,53

26/11/ 2021	14	3230	9 616,14	8	1489	4 422,56
29/11/ 2021	1	1	2,98	3	474	1 421,98
30/11/ 2021	6	1358	4 021,38	1	1	3,00
01/12/ 2021	5	474	1 412,47	4	1223	3 650,20
02/12/ 2021	24	2033	6 009,83	1	1	2,97
03/12/	11	2248	6 526,77	3	871	2 547,02
2021 06/12/	12	4419	12 446,10	15	3196	9 060,38
2021 07/12/	18	5162	14 387,96	11	2196	6 134,58
2021 08/12/	16	3822	10 655,28	16	4990	13 985,97
2021 09/12/	6	1018	2 842,83	1	1	2,80
2021 10/12/	8	925	2 557,53	1	1	2,80
2021 13/12/	7	2541	7 393,19	29	8590	25 035,24
2021 14/12/
2021 15/12/	4	1050	3 092,28	12	3266	9 724,74
2021	11	3647	10 939,66	9	2672	8 094,70
16/12/ 2021	5	383	1 145,17	4	885	2 653,79
17/12/ 2021	93	15001	63 380,90	119	22550	98 088,20
20/12/ 2021	54	7001	31 287,98	68	8201	36 836,38
21/12/ 2021	62	12301	56 420,66	62	12301	56 713,66
22/12/ 2021	28	6801	30 348,50	37	8501	38 174,50
23/12/ 2021	35	10001	46 254,64	42	11202	52 060,34
24/12/ 2021	11	3001	13 789,69	8	2001	9 244,69
27/12/20 21	96	73295	321 612,05	24	19145	85 632,92
28/12/	41	36097	151 338,73	45	37570	158 643,33
2021 29/12/	39	39629	166 774,13	47	40699	172 426,59
2021 30/12/	43	39268	165 308,75	33	41884	177 316,00
2021 31/12/	49	46541	198 631,12	40	43677	186 799,85
2021